Washington D.C., USA, 22-27 July 2012www.aids2012.org Why do we need patent landscapes and what tools can be made available? Presenting the UNDP Patent.

Slides:



Advertisements
Similar presentations
VANCOUVER GROUP MUTUAL EXPLOITATION Collaboration between UK, Canada and Australia Fatima Beattie Deputy Director General, IP Australia.
Advertisements

1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.
TVET working group contributions. What are the possible options for obtaining decent living and working conditions without joining the informal economy?
Consultative expert working group - proposals Barcelona
1 Advisory Council April 1, 2011 Child Care Development Fund – State Plan for Federal Fiscal Years 2012 and 2013.
1 EEC Board Meeting May 10, 2011 Child Care Development Fund – State Plan for Federal Fiscal Years 2012 and 2013.
Options appraisal, the business case & procurement
Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
WELCOME GHANAHR TRAINING. OUR VISION & MISSION OUR VISION To be the recognised Consultancy Firm with the highest ethical standard that delivers unrivalled.
2 nd WIPO Inter-Regional Meeting on South- South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement Cairo.
Patent settlements in the EU EGA perspective Ingrid Vandenborre 18 October 2013.
Government Rules of Sourcing An overview for suppliers June 2013.
PUENTE IN THE CARIBBEAN
Panorama of the pharmaceutical patenting and sanitary registration of ARVs drugs in Brazil: implications to access and to health industrial complex Pedro.
Intellectual Property Rights Regulations in Russia: Case of Government-Supported R&D Irina Dezhina Leading Researcher, Ph.D. Institute for the Economy.
First Evaluation of Good Governance for Medicines Programme Brief Summary of Findings.
LGAP’s Initiatives to Support Procurement in Local Government
GeneriKairos® making faster Generics. Molecule patent expiry date Later expiring patents - Need significant R&D, might delay generic drug development.
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
Recap of Day One Peter Chibatamoto. Opening Session Objectives of the workshop Opening remarks by NC – Cited a number of papers emphasizing the rationale.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.
1 Public Hearings: May , 2013 Child Care Development Fund Massachusetts State Plan Federal Fiscal Years 2014 and 2015.
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
A very short introduction to patents & access to medicines.
Advancing environmental sustainability in WHO/PAHO and in the health sector.
AUDREY R. CHAPMAN, PH.D. UNIVERSITY OF CONNECTICUT HEALTH CENTER INTELLECTUAL PROPERTY AND HUMAN RIGHTS MEETING PANEL 1: IP AND HEALTH FEBRUARY 21, 2013.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
Think IP Strategy Trusted advisors to the world’s most innovative companies Brisbane Beijing Chicago Goteborg Hyderabad Johannesburg Melbourne Mumbai Washington.
United Nations Statistics Division
Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.
Regional Intelligence in Central Macedonia, Greece The METAFORESIGHT solution Isidoros Passas, Nicos Komninos, Elena Sefertzi, Lina Kyrgiafini URENIO Research.
Washington D.C., USA, July 2012www.aids2012.org Human Resources Reinforcement in Health Logistics: A parternish between Burkina Faso’s Ministry of.
Data exclusivity, patents and registration of medicines Karin Timmermans TWN Regional Workshop Kuala Lumpur on bilateral trade agreements Aug
1 Introduction to Evaluating the Minnesota Demonstration Program Paint Product Stewardship Initiative September 19, 2007 Seattle, WA Matt Keene, Evaluation.
Policy options and recommendations José Palacín Chief, Innovative Policies Development UNECE Minsk, 19 June 2014.
Trade-related policies and access to medicines ICTSD Consultation on trade policy coherence and access to medicines Geneva November 7 th 2006,
Inventing the Future – The Role of Patents and Utility Models in Leveraging Technical Innovation in the Market Place Ron Marchant CB FRSA Implementation.
Anthony C. Tridico, Ph.D. AIPLA BIOTECHNOLOGY COMMITTEE Pinning Down a Moving Target: Patenting Biotech in Uncertain Times.
Dr. David Mowat June 22, 2005 Federal, Provincial & Local Roles Surveillance of Risk Factors and Determinants of Chronic Diseases.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
The Need to Address Disclosure of Origin Requirements in Patent Law Harmonization Initiatives Joshua D. Sarnoff Washington College of Law American University.
Federal Flexibility Initiative and Schoolwide Programs.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
Professionalizing Mobility Management: Developing Standards and Competencies Julie Dupree, Easter Seals Association of Travel Instruction Conference August.
Promotion of Innovation: Usefulness and value of Patent Information Andrew Czajkowski Head, Innovation and Technology Support Section Ulaanbaatar March.
Engagement and Cooperation on IAEA Safeguards – Additional Protocol: VERTIC Initiative and Methods 23 October 2014 IAEA Symposium on International Safeguards.
Washington D.C., USA, July 2012www.aids2012.org Treatment Monitoring & Advocacy Project: “Missing the Target Report Series” Othoman Mellouk ITPC-NA/ALCS.
DIS 605 BY DOROBIN AGOTI REG NO: D61/71443/2008 ICT INNOVATION, LEGAL AND PIRACY ISSUES.
Washington D.C., USA, July 2012www.aids2012.org Methodology to Determine the Patent Status of Key ARVs and Other Essential Medicines: A Strategy.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN LESOTHO REPORT OF DAY 1 Botha Tiheli, Masello.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.
Licensing & Transfer MIP International Patent Forum – 5 th April.
Task Force on Services Contracting Removing Federal Services Acquisition Barriers And Balancing Public and Private Interest Presentation to Defense Acquisition.
TRAFFIC/GFTN Legality Framework Ulrich Malessa, TRAFFIC Ian Gray, WWF GFTN.
Washington D.C., USA, July 2012www.aids2012.org An advocacy tool: Untangling the Web of Antiretroviral Price Reductions Arax Bozadjian HIV Focused.
How to Sell the Benefits of Marketing Procurement Internally.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
Software protection Copyright or Patent ? Software protections Copyright law Covers the source code Registration is only necessary to enforce infringement.
Washington D.C., USA, July 2012www.aids2012.org Sexual & Reproductive Health & Rights of Women living with HIV
National Qualifications Framework in the Republic of Moldova Veaceslav Nicic, LLL departament.
Niclas Morey, Director International Co-operation PCT developments at the EPO Partnership for Quality, Washington D.C.
Trade-related policies and access to medicines
Institutional Framework, Resources and Management
Income Eligible Re-Procurement
IP and legal issues Super-project.eu.
Presentation transcript:

Washington D.C., USA, July 2012www.aids2012.org Why do we need patent landscapes and what tools can be made available? Presenting the UNDP Patent Methodology Mandeep Dhaliwal, UNDP BDP, HIV/AIDS Practice Methodology co-authored by Barbara Milani and Cecilia Oh

Washington D.C., USA, July 2012www.aids2012.org The need for patent transparency Lack of transparency can hinder innovation or affordable access to health technologies Consequences include: (i) inappropriate claims of patent infringement; (ii) money wasted on unnecessary work-arounds; (iii)Undeserved licensing revenues; (iv)Blocked generic entry (v)Increased spending on procuring more expensive medicines, when cheaper options are available Transparency requirements should be key components of patent laws and systems In practice this is not the case

Washington D.C., USA, July 2012www.aids2012.org Patent Landscapes What is patent landscaping? How can it be used to improve procurement and supply? What tools can be used?

Washington D.C., USA, July 2012www.aids2012.org UNDP focuses on A Methodology that empowers relevant local officials to conduct patent searches Training local officials and procurement agencies to assess the validity of IP claims Preventing the granting of patents to undeserving applications by encouraging the refinement of patentability criteria

Washington D.C., USA, July 2012www.aids2012.org Public sources of information The Methodology relies on the US FDA Orange Book, the Health Canada Patent Register, and INAPDOC Why the Orange Book All patents submitted/listed by innovator companies, which are likely to seek the highest and longest patent protection in the US market Why the Health Canada Patent Register “Relevant” patents are listed after the revision carried by Health Canada, on the list of patents submitted by the innovator companies Why INPADOC International patent collection, contains patent families

Washington D.C., USA, July 2012www.aids2012.org Advantages and limitations Relies on open sources available free of charge, transparent Transfers research skills to and empowers local actors Has a multiplying effect ……………………………………………………………………. Does not cover medicines not in the Orange book and Health Canada (e.g. vaccines and biomedicines) For such medicines, a patent search would be necessary Is more complex than database use, requires training

Washington D.C., USA, July 2012www.aids2012.org The four steps

Washington D.C., USA, July 2012www.aids2012.org Process and desired outcomes UNDP intends to use of the patent search tool in low and middle income countries Bring together stakeholders –Pilot training workshops on the methodology and tool for health, –Procurement agencies and principal recipients – Patent landscaping exercises using the Methodology Desired outcomes: –Contribution to procurement cost-effectiveness –Legal certainty for current and future procurement –Cost savings from reduced IP assistance needs –Consistence with the TRIPS Agreement and its public health flexibilities

Washington D.C., USA, July 2012www.aids2012.org Thank you.